Compare Novartis with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALEMBIC PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALEMBIC PHARMA NOVARTIS/
ALEMBIC PHARMA
 
P/E (TTM) x 487.1 15.2 3,202.5% View Chart
P/BV x 28.3 3.5 807.2% View Chart
Dividend Yield % 1.6 1.1 148.5%  

Financials

 NOVARTIS   ALEMBIC PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ALEMBIC PHARMA
Mar-19
NOVARTIS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs758664 114.2%   
Low Rs579412 140.4%   
Sales per share (Unadj.) Rs228.4208.7 109.4%  
Earnings per share (Unadj.) Rs31.731.0 102.4%  
Cash flow per share (Unadj.) Rs32.837.1 88.3%  
Dividends per share (Unadj.) Rs10.005.50 181.8%  
Dividend yield (eoy) %1.51.0 146.4%  
Book value per share (Unadj.) Rs297.1144.2 206.0%  
Shares outstanding (eoy) m24.69188.52 13.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.6 113.5%   
Avg P/E ratio x21.117.4 121.3%  
P/CF ratio (eoy) x20.414.5 140.7%  
Price / Book Value ratio x2.23.7 60.3%  
Dividend payout %31.517.7 177.6%   
Avg Mkt Cap Rs m16,505101,461 16.3%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4457,467 19.4%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63939,347 14.3%  
Other income Rs m1,71894 1,831.9%   
Total revenues Rs m7,35739,441 18.7%   
Gross profit Rs m-638,736 -0.7%  
Depreciation Rs m251,152 2.2%   
Interest Rs m55184 30.0%   
Profit before tax Rs m1,5757,493 21.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,568 50.5%   
Profit after tax Rs m7845,844 13.4%  
Gross profit margin %-1.122.2 -5.0%  
Effective tax rate %50.320.9 240.2%   
Net profit margin %13.914.9 93.6%  
BALANCE SHEET DATA
Current assets Rs m9,52219,577 48.6%   
Current liabilities Rs m3,29614,896 22.1%   
Net working cap to sales %110.411.9 928.0%  
Current ratio x2.91.3 219.8%  
Inventory Days Days3790 40.8%  
Debtors Days Days2845 62.7%  
Net fixed assets Rs m4627,097 0.2%   
Share capital Rs m123377 32.7%   
"Free" reserves Rs m7,21326,811 26.9%   
Net worth Rs m7,33627,188 27.0%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m11,10547,778 23.2%  
Interest coverage x29.541.7 70.7%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.50.8 61.7%   
Return on assets %7.612.6 59.9%  
Return on equity %10.721.5 49.7%  
Return on capital %22.223.6 94.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6119,453 0.3%   
Fx outflow Rs m3,6306,065 59.9%   
Net fx Rs m-3,57013,388 -26.7%   
CASH FLOW
From Operations Rs m1,6108,120 19.8%  
From Investments Rs m687-7,556 -9.1%  
From Financial Activity Rs m-2,677590 -453.3%  
Net Cashflow Rs m-3801,153 -32.9%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 2.9 69.0%  
FIIs % 1.6 9.1 17.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 13.9 154.7%  
Shareholders   41,647 49,328 84.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 13, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS